Healthcare provider profile · identity verified

Matthew Hallowell, MD

Family Practice · RENTON, WA · NPI 1467814871

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	420	111
Amlodipine Besylate	Amlodipine Besylate	347	97
Lisinopril	Lisinopril	258	73
Losartan Potassium	Losartan Potassium	234	65
Rosuvastatin Calcium	Rosuvastatin Calcium	214	64
Gabapentin	Gabapentin	183	43
Levothyroxine Sodium	Levothyroxine Sodium	183	42
Hydrochlorothiazide	Hydrochlorothiazide	182	49
Metoprolol Succinate	Metoprolol Succinate	172	44
Metformin Hcl Er	Metformin Hcl	136	38
Tamsulosin Hcl	Tamsulosin Hcl	133	49
Omeprazole	Omeprazole	107	34
Trazodone Hcl	Trazodone Hcl	107	22
Simvastatin	Simvastatin	102	30
Furosemide	Furosemide	90	28
Meloxicam	Meloxicam	88	43
Tramadol Hcl	Tramadol Hcl	83	17
Azelastine Hcl	Azelastine Hcl	82	40
Pantoprazole Sodium	Pantoprazole Sodium	80	25
Sertraline Hcl	Sertraline Hcl	78	24
Glipizide	Glipizide	77	23
Metformin Hcl	Metformin Hcl	77	20
Eliquis	Apixaban	66	17
Carvedilol	Carvedilol	64	16
Fluticasone Propionate	Fluticasone Propionate	63	19
Pregabalin	Pregabalin	62	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	15
Finasteride	Finasteride	59	16
Pravastatin Sodium	Pravastatin Sodium	55	17
Potassium Chloride	Potassium Chloride	50	14
Albuterol Sulfate Hfa	Albuterol Sulfate	49	21
Escitalopram Oxalate	Escitalopram Oxalate	44	suppressed
Allopurinol	Allopurinol	43	13
Lorazepam	Lorazepam	42	suppressed
Benazepril Hcl	Benazepril Hcl	41	11
Ozempic	Semaglutide	41	suppressed
Buspirone Hcl	Buspirone Hcl	40	suppressed
Ezetimibe	Ezetimibe	40	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	suppressed
Divalproex Sodium	Divalproex Sodium	38	suppressed
Famotidine	Famotidine	37	11
Alendronate Sodium	Alendronate Sodium	36	11
Clopidogrel	Clopidogrel Bisulfate	35	suppressed
Prednisone	Prednisone	34	27
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Irbesartan	Irbesartan	31	suppressed
Jardiance	Empagliflozin	31	suppressed
Alprazolam	Alprazolam	30	12
Hydroxyzine Hcl	Hydroxyzine Hcl	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	20
Atenolol	Atenolol	27	suppressed
Telmisartan	Telmisartan	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Glimepiride	Glimepiride	22	suppressed
Methocarbamol	Methocarbamol	22	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Nitroglycerin	Nitroglycerin	20	suppressed
Clonazepam	Clonazepam	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	11
Lovastatin	Lovastatin	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Mupirocin	Mupirocin	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Ramipril	Ramipril	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Valsartan	Valsartan	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	12
Estradiol	Estradiol	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Arnuity Ellipta	Fluticasone Furoate	13	suppressed
Azithromycin	Azithromycin	13	13
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	11
Prazosin Hcl	Prazosin Hcl	13	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	13	suppressed
Sprintec	Norgestimate-Ethinyl Estradiol	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Brilinta	Ticagrelor	12	suppressed
Diazepam	Diazepam	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error